# Assign first-line treatment in diffuse large B-cell lymphoma by genetic subtype, not by a three-antibody stain

Source: https://onco.cc/ideas/lymphoma-ev-genetic-subtype-directed-first-line/  
OnCo record `lymphoma-ev-genetic-subtype-directed-first-line` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Three genetic classifications of the commonest aggressive lymphoma exist and none of them yet decides anyone's treatment. The trial that would change that has not been run.

## Summary

The obstacles are concrete rather than conceptual. Comprehensive classification needs copy number and structural variants as well as mutations, which routine panels do not generate; a turnaround time short enough to decide first-line treatment in an aggressive lymphoma means days, not weeks; and a proportion of tumours remain unclassified by design. Any trial has to report that proportion honestly, because a classifier that works on two-thirds of patients is a different clinical proposition from one that works on all of them. The training cohorts were also largely of European ancestry, which is a validation gap rather than a flaw.

## Fields

- Kind: Idea
- Last checked: 2026-10-01
- Also known as: LymphGen-directed first-line therapy; Genetic subtype-directed treatment in diffuse large B-cell lymphoma
- Tags: lymphoma-evidence
- Hypothesis: Assigning first-line treatment in diffuse large B-cell lymphoma by LymphGen genetic subtype improves progression-free survival over assigning it by cell-of-origin immunohistochemistry or by giving everyone R-CHOP.
- Rationale: Schmitz showed that two of the four genetic subtypes, MCD and BN2, depend on chronic active B-cell receptor signalling, which Bruton tyrosine kinase inhibitors block, and that outcomes differ sharply between subtypes after immunochemotherapy. PHOENIX, which selected by the non-germinal-centre immunohistochemistry phenotype rather than by genetics, failed overall while producing long remissions in a subgroup. Wright's LymphGen tool makes per-patient classification possible with a probability attached. The pieces exist; nobody has put them in a randomised trial of first-line treatment.
- Proposed test: A randomised first-line trial in diffuse large B-cell lymphoma with comprehensive genomic profiling at diagnosis, assigning treatment by LymphGen subtype in the experimental arm (a Bruton tyrosine kinase inhibitor or a BCL2 inhibitor added to R-CHOP for the subtypes predicted to benefit, standard R-CHOP for the rest) against R-CHOP for everyone, powered on progression-free survival, with the proportion of tumours successfully classified reported as a co-primary feasibility endpoint.
- Maturity: preclinical-evidence
- Actor: research

## Connected records

- roadmaps: [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/)
- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Whole-exome & whole-genome sequencing](https://onco.cc/technologies/wes-wgs/)
- terms: [Cell of origin (GCB vs ABC)](https://onco.cc/terms/cell-of-origin/), [Next-generation sequencing (NGS)](https://onco.cc/terms/ngs/)
- targets: [BCL-2](https://onco.cc/targets/bcl2/), [BTK (Bruton tyrosine kinase)](https://onco.cc/targets/btk/), [CD79b](https://onco.cc/targets/cd79b/), [EZH2](https://onco.cc/targets/ezh2/), [MYD88](https://onco.cc/targets/myd88/)
- bottlenecks: [Biomarkers are not validated or standardised](https://onco.cc/bottlenecks/b-biomarker-validation/), [The valley of death between lab and product](https://onco.cc/bottlenecks/b-translational-valley/), [Trial design, endpoints and cost](https://onco.cc/bottlenecks/b-trial-design/)
- key papers: [A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications](https://onco.cc/key-papers/paper-wright-lymphgen-genetic-subtypes-dlbcl-cancer-cell-2020/), [Genetics and pathogenesis of diffuse large B-cell lymphoma](https://onco.cc/key-papers/paper-schmitz-genetics-pathogenesis-dlbcl-nejm-2018/), [Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes](https://onco.cc/key-papers/paper-chapuy-molecular-subtypes-dlbcl-nat-med-2018/), [Randomized phase III trial of ibrutinib and R-CHOP in non-germinal centre B-cell diffuse large B-cell lymphoma (PHOENIX)](https://onco.cc/key-papers/paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019/)

---
JSON: https://onco.cc/api/v1/entities/lymphoma-ev-genetic-subtype-directed-first-line.json